The Asia Pacific Topical Wound Agents Market would witness market growth of 9.5% CAGR during the forecast period (2023-2030).
Advanced wound dressings, including foam dressings, hydrogels, hydrocolloids, and films, are in demand due to their ability to create an optimal wound-healing environment and promote faster healing rates. These products are used to clean and disinfect wounds to prevent infection. They often contain iodine, hydrogen peroxide, chlorhexidine, or alcohol. Numerous chronic conditions have contributed in the quantity of surgical procedures conducted. More frequently, topical wound treatments are applied to prevent surgical site infections. The majority of surgical injuries following cancer surgery are more significant and more profound, discharging fluids that require routine management. Enzyme-based formulation products significantly reduce the risk of infection while aiding in managing considerable bruising. Consequently, the rising incidence of chronic ailments and surgical site infections is expected to stimulate the market by increasing demand.
Furthermore, antimicrobial and antiseptic topical wound agents continue to be in demand due to the emphasis on infection prevention and control, particularly in healthcare settings dealing with acute and chronic wounds. Topical agents to accelerate wound healing processes, reduce healing time, and promote tissue regeneration have gained attention in recent years. These products focus on providing an optimal environment for faster and more efficient wound closure.
The effects of diabetic foot ulcers on the market highlight the necessity for specialized products that effectively tackle the distinct obstacles associated with these persistent wounds. Continuous innovation, research, and development in wound care technology and products are crucial to improving outcomes for individuals with diabetic foot ulcers. Therefore, the rising cases of diabetic foot ulcers in the Asia Pacific region propel the growth of the market.
The China market dominated the Asia Pacific Topical Wound Agents Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $180.3 million by 2030. The Japan market is exhibiting a CAGR of 8.7% during (2023 - 2030). Additionally, The India market would experience a CAGR of 10.1% during (2023 - 2030).
Based on End-use, the market is segmented into Hospitals, Clinics, and Others. Based on Application, the market is segmented into Chronic Wounds (Diabetic Foot Ulcers, Pressure Ulcers, Venous Leg Ulcers, and Others), and Acute Wounds (Surgical & Traumatic, and Burns). Based on Product, the market is segmented into Creams, Gels, Sprays, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Smith & Nephew PLC, Teva Pharmaceutical Industries Ltd., Molnlycke Health Care AB, Viatris, Inc. (Mylan N.V.), AstraZeneca PLC, Coloplast Group, Novartis AG, Pfizer Inc., Johnson & Johnson (Johnson & Johnson Services, Inc.), and ConvaTec Group PLC.
Advanced wound dressings, including foam dressings, hydrogels, hydrocolloids, and films, are in demand due to their ability to create an optimal wound-healing environment and promote faster healing rates. These products are used to clean and disinfect wounds to prevent infection. They often contain iodine, hydrogen peroxide, chlorhexidine, or alcohol. Numerous chronic conditions have contributed in the quantity of surgical procedures conducted. More frequently, topical wound treatments are applied to prevent surgical site infections. The majority of surgical injuries following cancer surgery are more significant and more profound, discharging fluids that require routine management. Enzyme-based formulation products significantly reduce the risk of infection while aiding in managing considerable bruising. Consequently, the rising incidence of chronic ailments and surgical site infections is expected to stimulate the market by increasing demand.
Furthermore, antimicrobial and antiseptic topical wound agents continue to be in demand due to the emphasis on infection prevention and control, particularly in healthcare settings dealing with acute and chronic wounds. Topical agents to accelerate wound healing processes, reduce healing time, and promote tissue regeneration have gained attention in recent years. These products focus on providing an optimal environment for faster and more efficient wound closure.
The effects of diabetic foot ulcers on the market highlight the necessity for specialized products that effectively tackle the distinct obstacles associated with these persistent wounds. Continuous innovation, research, and development in wound care technology and products are crucial to improving outcomes for individuals with diabetic foot ulcers. Therefore, the rising cases of diabetic foot ulcers in the Asia Pacific region propel the growth of the market.
The China market dominated the Asia Pacific Topical Wound Agents Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $180.3 million by 2030. The Japan market is exhibiting a CAGR of 8.7% during (2023 - 2030). Additionally, The India market would experience a CAGR of 10.1% during (2023 - 2030).
Based on End-use, the market is segmented into Hospitals, Clinics, and Others. Based on Application, the market is segmented into Chronic Wounds (Diabetic Foot Ulcers, Pressure Ulcers, Venous Leg Ulcers, and Others), and Acute Wounds (Surgical & Traumatic, and Burns). Based on Product, the market is segmented into Creams, Gels, Sprays, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Smith & Nephew PLC, Teva Pharmaceutical Industries Ltd., Molnlycke Health Care AB, Viatris, Inc. (Mylan N.V.), AstraZeneca PLC, Coloplast Group, Novartis AG, Pfizer Inc., Johnson & Johnson (Johnson & Johnson Services, Inc.), and ConvaTec Group PLC.
Scope of the Study
Market Segments Covered in the Report:
By End-use- Hospitals
- Clinics
- Others
- Chronic Wounds- Diabetic Foot Ulcers
- Pressure Ulcers
- Venous Leg Ulcers
- Others
- Acute Wounds- Surgical & Traumatic
- Burns
- Creams
- Gels
- Sprays
- Others
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Smith & Nephew PLC
- Teva Pharmaceutical Industries Ltd.
- Molnlycke Health Care AB
- Viatris, Inc. (Mylan N.V.)
- AstraZeneca PLC
- Coloplast Group
- Novartis AG
- Pfizer Inc.
- Johnson & Johnson (Johnson & Johnson Services, Inc.)
- ConvaTec Group PLC
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Asia Pacific Topical Wound Agents Market by End-use
Chapter 5. Asia Pacific Topical Wound Agents Market by Application
Chapter 6. Asia Pacific Topical Wound Agents Market by Product
Chapter 7. Asia Pacific Topical Wound Agents Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Smith & Nephew PLC
- Teva Pharmaceutical Industries Ltd.
- Molnlycke Health Care AB
- Viatris, Inc. (Mylan N.V.)
- AstraZeneca PLC
- Coloplast Group
- Novartis AG
- Pfizer Inc.
- Johnson & Johnson (Johnson & Johnson Services, Inc.)
- ConvaTec Group PLC
Methodology
LOADING...
